$36,000
$25,176

More on CD47 as a Potentially Broad Cancer Therapy Target

All commonalities in cancer are interesting, as part of the high cost of dealing with cancer is based on the many, many different varieties and the great variability of its biochemistry even between individual tumors. Anything that is common between many types of cancer and between tumors offers a possibility of a lower-cost and broader therapy. The cell surface marker CD47 has shown up of late as a possible commonality, and work continues to see whether a therapy can be built on this:

A decade ago, [researchers] discovered that leukemia cells produce higher levels of a protein called CD47 than do healthy cells. CD47 [is] also displayed on healthy blood cells; it's a marker that blocks the immune system from destroying them as they circulate. Cancers take advantage of this flag to trick the immune system into ignoring them. In the past few years, [researchers] showed that blocking CD47 with an antibody cured some cases of lymphomas and leukemias in mice by stimulating the immune system to recognize the cancer cells as invaders. Now, [researchers] have shown that the CD47-blocking antibody may have a far wider impact than just blood cancers.

"What we've shown is that CD47 isn't just important on leukemias and lymphomas. It's on every single human primary tumor that we tested." Moreover, [the scientists] found that cancer cells always had higher levels of CD47 than did healthy cells. How much CD47 a tumor made could predict the survival odds of a patient. To determine whether [targeting] CD47 was beneficial, the scientists exposed tumor cells to macrophages, a type of immune cell, and anti-CD47 molecules in petri dishes. Without the drug, the macrophages ignored the cancerous cells. But when the CD47 was [targeted], the macrophages engulfed and destroyed cancer cells from all tumor types.

Next, the team transplanted human tumors into the feet of mice, where tumors can be easily monitored. When they treated the rodents with anti-CD47, the tumors shrank and did not spread to the rest of the body. In mice given human bladder cancer tumors, for example, 10 of 10 untreated mice had cancer that spread to their lymph nodes. Only one of 10 mice treated with anti-CD47 had a lymph node with signs of cancer. Moreover, the implanted tumor often got smaller after treatment - colon cancers transplanted into the mice shrank to less than one-third of their original size, on average.

Link: http://news.sciencemag.org/sciencenow/2012/03/one-drug-to-shrink-all-tumors.html

Comments

I'm suffer from Higrade t1 bladder cancer. Can CD47 be used for treatment?

Posted by: Martin Schmitt at March 31st, 2013 8:54 AM

How can a patient sign up for this testing?

Posted by: Val at April 1st, 2013 12:17 PM

a friend of mine has malignant melanoma with mets to his kidneys, bone c-spine lower extremities bilaterally. have there been studies to evaluate the use of curcumin in this case with respect to treatment options. i have not found significant studies articulating the efficacy with the use of this herbal product.

Posted by: rzb m.d. at April 3rd, 2013 1:05 AM

Does this work on bone cancers aswell?

Posted by: Barry at April 7th, 2013 12:18 PM

how do you sign up for those treatments?Dose it work on liver and bone?

Posted by: erika garcias at May 7th, 2013 9:14 PM

breast cancer stage 4 in the bone well this help ??

Posted by: irma mexia at February 20th, 2014 2:36 PM

Post a comment; thoughtful, considered opinions are valued. Comments incorporating ad hominem attacks, advertising, and other forms of inappropriate behavior are likely to be deleted.

Note that there is a comment feed for those who like to keep up with conversations.